Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s ...

The event brought together 300 researchers, clinicians, industry leaders, and entrepreneurs to highlight their work.

In this paper the authors have identified two new participants in the damage-response pathway, using cells from patients with ataxia-telangiectasia [AT], a disease characterized by hypersensitivity to ...

and four (ataxia-telangiectasia, ataxia-telangiectasia-like disorder, Nijmegen breakage syndrome and Alzheimer's disease) exhibit defects in genes involved in repairing double-strand breaks.